UPB Latest Press Releases

-- September 8, 2026 --

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 Globe Newswire 3:30 AM

-- September 1, 2026 --

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP Globe Newswire 7:00 AM

-- August 11, 2026 --

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Globe Newswire 7:00 AM

-- June 14, 2026 --

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Globe Newswire 10:00 AM

-- June 8, 2026 --

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 Globe Newswire 7:00 AM

-- June 3, 2026 --

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes